Table 2.
EVR Pharmacokinetic Properties for the Entire Cohort and for those that Received Tacrolimus CNI Therapy
| Characteristic | Entire Study Cohort | CyA Patients Removed | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| AA | C | p-Value | AA | C | p-Value | |
|
| ||||||
| (n=22) | (n=21) | (n=21) | (n=18) | |||
|
| ||||||
| Mean EVR Level 1st 30 Days | 4.7±4.1 | 2.9±2.0 | 0.071 | 4.4±3.9 | 2.7±1.8 | 0.082 |
|
| ||||||
| EVR Levels 1st 30 Days of Therapy | ||||||
| >3 ng/mL | 68% | 43% | 0.129 | 67% | 39% | 0.083 |
| >6 ng/mL | 36% | 5% | 0.011 | 33% | 0% | 0.007 |
| >8 ng/mL | 23% | 0% | 0.020 | 19% | 0% | 0.051 |
|
| ||||||
| Mean EVR Level 1st 60 Days | 4.8±3.6 | 3.2±2.2 | 0.075 | 4.6±3.6 | 2.9±1.8 | 0.068 |
|
| ||||||
| EVR Levels 1st 60 days of Therapy | ||||||
| >3 ng/mL | 68% | 43% | 0.129 | 67% | 39% | 0.083 |
| >6 ng/mL | 36% | 10% | 0.037 | 33% | 6% | 0.032 |
| >8 ng/mL | 23% | 5% | 0.089 | 19% | 0% | 0.051 |
|
| ||||||
| Average EVR Levels | ||||||
| <3 ng/mL | 18% | 62% | 0.003 | 19% | 67% | 0.003 |
| <6 ng/mL | 59% | 76% | 0.042 | 62% | 83% | 0.138 |
| <8 ng/mL | 82% | 92% | 0.413 | 86% | 94% | 0.370 |
|
| ||||||
| Starting EVR Dose (mg/day) | 2.1±0.8 | 1.6±0.6 | 0.036 | 2.0±0.8 | 1.6±0.5 | 0.044 |
| Mean EVR Dose (mg/day) | 2.6±1.1 | 2.2±0.7 | 0.152 | 2.6±1.1 | 2.2±0.8 | 0.194 |
| Mean Concentration-to-Dose Ratio | 2.5±1.6 | 2.0±1.7 | 0.360 | 2.4±1.6 | 1.9±1.7 | 0.376 |